Explore Ingrezza Valbenazine and Its Role in Movement Disorders

Movement disorders can cause involuntary or poorly controlled movements that affect daily activities and quality of life. Ingrezza, whose active ingredient is valbenazine, is a vesicular monoamine transporter 2 inhibitor. The U.S. Food and Drug Administration has approved it for adults with tardive dyskinesia and for chorea associated with Huntington disease.

Understanding Ingrezza Valbenazine and Its Uses

Valbenazine works by inhibiting VMAT2, a protein involved in transporting certain neurotransmitters into nerve cells. By modifying this process, the medicine can help reduce abnormal involuntary movements in appropriate patients.

Tardive dyskinesia is a movement disorder that may develop after exposure to certain medications, particularly some antipsychotic medicines. Symptoms can include repetitive movements involving the face, tongue, torso, limbs, fingers, or toes. Huntington disease chorea, meanwhile, involves involuntary, irregular movements associated with the progressive neurological condition.

Important points about its role include:

• Ingrezza is approved for adults with tardive dyskinesia.
• It is also approved for chorea associated with Huntington disease.
• It is taken orally and may be taken with or without food.
• The recommended dosage and adjustments depend on the condition, response, tolerability, and certain patient factors.
• Treatment should be prescribed and monitored by a healthcare professional.

Dosage Considerations and Important Safety Information

The prescribing information lists an initial dosage of 40 mg once daily for both approved uses. For tardive dyskinesia, the recommended dosage is generally increased to 80 mg once daily after one week. For Huntington disease chorea, the dosage can be increased in 20 mg increments every two weeks, with 80 mg once daily listed as the recommended dosage. Lower doses may be considered based on response and tolerability.

Safety considerations are important when evaluating valbenazine. The prescribing information includes a boxed warning concerning depression and suicidal thoughts or behavior in patients with Huntington disease. Other warnings include sleepiness or sedation, QT interval prolongation, neuroleptic malignant syndrome, and Parkinson-like symptoms.

Key considerations include:

• Patients with Huntington disease should be monitored for worsening depression or suicidal thoughts and behavior.
• Sleepiness or sedation can affect activities requiring alertness, including driving.
• Certain heart rhythm conditions may require avoiding the medicine.
• Drug interactions can affect the appropriate dosage.
• People with moderate or severe liver impairment or known CYP2D6 poor metabolism may require a lower recommended dosage.

The most common adverse reaction identified for tardive dyskinesia is somnolence. For Huntington disease chorea, commonly reported adverse reactions include somnolence, lethargy or sedation, rash, urticaria, and insomnia. Individual experiences can vary, so medical advice should be sought if concerning symptoms occur.

Ingrezza valbenazine has an established role in the management of specific adult movement disorders, particularly tardive dyskinesia and Huntington disease associated chorea. Its action as a VMAT2 inhibitor can help address abnormal involuntary movements, while dosing and safety considerations require individualized medical supervision. Information about valbenazine should be used for educational purposes and does not replace advice from a qualified healthcare professional.